Durlobactam May Be Active in Treating Mycobacterium abscessus

In vitro studies suggest that the beta-lactamase inhibitor durlobactam — particularly when combined with a beta-lactam — should be evaluated in clinical trials for treatment of patients with M. abscessus infections.

Intrinsic antibiotic resistance along with concurrent host immunosuppression present formidable challenges when treating Mycobacterium abscessus infections (particularly those affecting the lungs). Expanding the therapeutic repertoire available to these patients would serve a great medical need. In a series of in vitro studies, Shin et al. assessed various beta-lactams (BLs) and beta-lactamase inhibitors (BLIs) to evaluate the possible dual action of BLIs such as durlobactam (DUR). These actions consisted of simultaneous inhibition of BL hydrolysis and inhibition of bacterial cell wall synthesizing L,D-transpeptidases (LDT) and D,D-carboxypeptidases (also known as penicillin-binding proteins [PBPs]).

DUR inactivated the beta-lactamase of M. …

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases